Further reductions in LDL cholesterol through more intensive statin regimens safely produce definite further reductions in vascular events, even down to very low LDL levels, lower than current targets, according to the results of 2 meta-analyses, The Lancet reported. There was no evidence of any lower threshold where the benefit is not seen.
Further reductions in low-density lipoprotein (LDL) cholesterol through more intensive statin regimens safely produce definite further reductions in vascular events, even down to very low LDL levels, lower than current targets, according to the results of 2 meta-analyses, The Lancet reported. There was no evidence of any lower threshold where the benefit is not seen.
Researchers said that each 1-mmol/L LDL cholesterol reduction reduces the risk of occlusive vascular events by approximately 20%, irrespective of baseline cholesterol concentration, which implies that a 2- to 3-mmol/L reduction would reduce risk by about 40% to 50%. According to researchers, the findings suggest that the primary goal for patients at high risk of occlusive vascular events should be to achieve the largest LDL-cholesterol reduction possible without materially increasing myopathy risk.
In contrast to current therapeutic guidelines, which tend to emphasize particular LDL-cholesterol targets, this research suggested that lowering LDL cholesterol further in high-risk patients who achieve such targets would produce additional benefits, without an increased risk of cancer, nonvascular mortality, or other safety issue, said Anthony Keech, a professor of medicine, cardiology, and epidemiology at the University of Sydney in Australia.
The meta-analyses were conducted by the Cholesterol Treatment Trialists’ Collaboration, which includes researchers from both the University of Oxford (United Kingdom) and the National Health and Medical Research Council Clinical Trials Centre at the University of Sydney.
Pharmacists Play Unique Role in Advancing Health Equity for Patients With Chronic Disease
December 7th 2023A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.
Assessing Financial Impacts of Pharmacist-Led Interventions in Pediatric Ambulatory Care
December 5th 2023According to a poster abstract presented at the ASHP Midyear Clinical Meeting & Exhibition, specialty pharmacy services were used for a variety of conditions that have been reported in adult populations.